Home > Neurology > ECTRIMS 2021 > COVID-19 > Immunotherapy in MS does not influence COVID-19 severity and mortality

Immunotherapy in MS does not influence COVID-19 severity and mortality

Presented By
Dr Gabriel Bsteh, Medical University of Vienna, Austria
Conference
ECTRIMS 2021
A population-based MS cohort found COVID-19 severity and mortality to depend on age, comorbidity, and degree of disability. Exposure to disease-modifying therapy (DMT) and immunosuppressive DMT was not an essential factor, except for CD20 inhibitors. This adds to the evidence that COVID-19 risk can be individually anticipated in MS patients and, except possibly for those on anti-CD20 therapies, does not generally influence treatment decisions [1–3]. The objective of this Austrian, nationwide, population-based study was to characterise the prevalence, severity, and overall mortality of SARS-CoV-2 infection in MS patients associated with a specific DMT. Dr Gabriel Bsteh (Medical University of Vienna, Austria) explained that the study included MS patients aged ≥18 years with COVID-19 diagnosed between 1 January 2020 and 30 April 2021. COVID-19 course was classified as either mild (no hospitalisation), severe, or fatal. Overall, 126 MS patients with COV...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on